These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37851321)

  • 1. Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular Lymphoma.
    Sanchez Alvarez J; Jaber M; Blanchet Zumofen MH
    Oncol Ther; 2023 Dec; 11(4):495-511. PubMed ID: 37851321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy.
    McGough SF; Shamas N; Wang J; Jaber M; Swarup B; Blanchet Zumofen MH; Lautié B; Parreira J; Wei MC; Shewade A
    Leuk Lymphoma; 2023 Dec; 64(14):2269-2278. PubMed ID: 37840271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
    Maurer MJ; Casulo C; Larson MC; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P; Cohen JB; Kahl BS; Burack WR; Koff JL; Mun Y; Masaquel A; Wu M; Wei MC; Shewade A; Li J; Cerhan JR; Link BK; Flowers CR
    Haematologica; 2024 Jul; 109(7):2177-2185. PubMed ID: 38031804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
    Budde LE; Sehn LH; Matasar M; Schuster SJ; Assouline S; Giri P; Kuruvilla J; Canales M; Dietrich S; Fay K; Ku M; Nastoupil L; Cheah CY; Wei MC; Yin S; Li CC; Huang H; Kwan A; Penuel E; Bartlett NL
    Lancet Oncol; 2022 Aug; 23(8):1055-1065. PubMed ID: 35803286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
    Bosch F; Kuruvilla J; Vassilakopoulos TP; Maio DD; Wei MC; Zumofen MB; Nastoupil LJ
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):105-121. PubMed ID: 37981564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
    Matarasso S; Assouline S
    Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients.
    van Hest N; Morten P; Stubbs K; Trevor N
    J Health Econ Outcomes Res; 2023; 10(1):1-9. PubMed ID: 36688213
    [No Abstract]   [Full Text] [Related]  

  • 8. Mosunetuzumab for the treatment of follicular lymphoma.
    Labanca C; Martino EA; Vigna E; Bruzzese A; Mendicino F; De Luca P; Lucia E; Olivito V; Fragliasso V; Neri A; Morabito F; Gentile M
    Expert Opin Biol Ther; 2024 Oct; 24(10):1039-1048. PubMed ID: 39259182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Munakata W; Izutsu K; Mishima Y; Nagai H; Ishihara Y; Suzumiya J; Kanakura Y; Nanki T; Miyake T; Kawasaki A; Yoshinaga T; Ishizawa K
    Jpn J Clin Oncol; 2023 Oct; 53(10):912-921. PubMed ID: 37486002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
    Wilkinson S; Gupta A; Scheuer N; Mackay E; Arora P; Thorlund K; Wasiak R; Ray J; Ramagopalan S; Subbiah V
    JAMA Netw Open; 2021 Oct; 4(10):e2126306. PubMed ID: 34618040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.
    Chaudhary MA; Edmondson-Jones M; Baio G; Mackay E; Penrod JR; Sharpe DJ; Yates G; Rafiq S; Johannesen K; Siddiqui MK; Vanderpuye-Orgle J; Briggs A
    Med Decis Making; 2023 Jan; 43(1):91-109. PubMed ID: 36259353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Bartlett NL; Assouline S; Giri P; Schuster SJ; Cheah CY; Matasar M; Gregory GP; Yoon DH; Shadman M; Fay K; Yoon SS; Panizo C; Flinn I; Johnston A; Bosch F; Sehn LH; Wei MC; Yin S; To I; Li CC; Huang H; Kwan A; Penuel E; Budde LE
    Blood Adv; 2023 Sep; 7(17):4926-4935. PubMed ID: 37067952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data.
    Moran M; Nickens D; Adcock K; Bennetts M; Desscan A; Charnley N; Fife K
    Target Oncol; 2019 Aug; 14(4):405-416. PubMed ID: 31301015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma.
    Palmer S; Lin Y; Martin TG; Jagannath S; Jakubowiak A; Usmani SZ; Buyukkaramikli N; Phelps H; Slowik R; Pan F; Valluri S; Pacaud L; Jackson G
    Oncol Ther; 2023 Sep; 11(3):313-326. PubMed ID: 37270762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of different censoring methods for analyzing survival using real-world data with linked mortality information: a simulation study.
    Hsu WC; Crowley A; Parzynski CS
    BMC Med Res Methodol; 2024 Sep; 24(1):203. PubMed ID: 39272007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data.
    Tan K; Bryan J; Segal B; Bellomo L; Nussbaum N; Tucker M; Torres AZ; Bennette C; Capra W; Curtis M; Miksad RA
    Clin Pharmacol Ther; 2022 Jan; 111(1):168-178. PubMed ID: 34197637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting.
    Cao Y; Marcucci EC; Budde LE
    J Hematol Oncol; 2023 Jun; 16(1):69. PubMed ID: 37381053
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.